Evidence map›Paper›PMID 35264466›Full record

ArticleBiomolecules & therapeutics2022

Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects.

Hyo Jeong Lee, Yeongyu Moon, Jungil Choi, Jeong Doo Heo, Sekwang Kim, Hari Krishna Nallapaneni, Young-Won Chin, Jongkook Lee, Sun-Young Han

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Hyo Jeong LeeCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea.
Yeongyu MoonGyeongnam Biohealth Research Center, Gyeongnam Branch Institute, Korea Institute of Toxicology, Jinju 52834, Republic of Korea.
Jungil ChoiGyeongnam Biohealth Research Center, Gyeongnam Branch Institute, Korea Institute of Toxicology, Jinju 52834, Republic of Korea.
Jeong Doo HeoGyeongnam Biohealth Research Center, Gyeongnam Branch Institute, Korea Institute of Toxicology, Jinju 52834, Republic of Korea.
Sekwang KimCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea.
Hari Krishna NallapaneniCollege of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea.
Young-Won ChinCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.
Jongkook LeeCollege of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea.
Sun-Young HanCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea.
Gyeongsang National University · KRKorea Institute of Toxicology · KRKangwon National University · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tropomyosin receptor kinase A (TrkA) protein is a receptor tyrosine kinase encoded by the

Indexed as

Colon cancerKRC-108Neurotrophic receptor kinase 1 fusionTropomyosin receptor kinase A

Identifiers

PMID35264466
PMCPMC9252884
OpenAlexW4220885074

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.